Drug Profile
Budesonide hydrofluoroalkane inhalation - Chiesi
Alternative Names: Budesonide HFA inhalation - Chiesi; Budesonide Modulite; Budiair; S 1320 HFA inhalation - ChiesiLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Chiesi Farmaceutici
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 31 Jan 2003 First global launch of budesonide Modulite® in Germany
- 31 Jan 2003 Launched for Asthma in Germany (Inhalation)
- 23 Jan 2003 Registered for Asthma in Germany (Inhalation)